-
Combo Chemo w/ or w/o Torisel Treating Rhabdomyosarcoma
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
-
Rituximab in Patients with High Risk Lymphoma
A Randomized Phase II study of Brentuximab Vedotin and Crizotinib in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL)
-
Treatment of Germ Cell Tumor w/Chemo and Radiation
Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT): A Groupwide Phase II Study
-
Treatment of Pediatric Patients w/High Risk Leukemia
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum A Groupwide Phase III Study
-
Azacitidine & Combo Chemo in Treating Infants W/ALL & KMT2A
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
-
Closure of Muscular Ventricular Septal Defects with the Amplatzer Muscular VSD Occluder Post Approval Study
Closure of Muscular Ventricular Septal Defects with the Amplatzer Muscular VSD Occluder Post Approval Study
-
Study of AeroVanc for the Treatment of Persistent MRSA in CF
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AeroVanc for the Treatment of Persistent Methicillin-Resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients (SAV005-04)
-
Study to Evaluate the Safety and Efficacy of MEDI8897 for RSV
A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
-
A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA
Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who Are Homozygous for the F508del-CFTR Mutation
-
Combo Chemo Treating Newly Diagnosed Metastatic Ewing Sarcoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma